OABI OmniAb, Inc. stock chart & analysis
Conviction 28HealthcareScan · Fri, Nov 6, 2026OmniAb, Inc. (OABI) closed at $5.03 (+4.14%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 54, RS Rating 99, -7.5% from its 52-week high, +171.3% year to date. Sector: Healthcare · Services-Commercial Physical & Biological Research.
Why OABI moved
From the StockSetups movers recaps that covered OABI, newest first. A recap states what was known that day.
- Close+36.6%
No catalyst headline is on file in today's data, so the specific trigger is unclear. Given the broader earnings-season context and the stock's behavior — a gap to 52-week highs with a clean continuation — investors may be reacting to news not captured in today's data set.
Top Stock Movers Today — August 7, 2026: Why WWR, VATE, RCEL, QNST & OABI Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
OABI technical analysis
Trend
OABI is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 6.9% above the 50-day ($4.70) and 80.6% above the 200-day ($2.78). ADX(14) at 19 points to a weak trend — more range than direction. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 54, in the bullish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 1.4× its 20-day average. It trades about $7.0M a day on average. ATR(14) is $0.3641, 7.2% of price — its typical daily range. Bollinger Bands are in a squeeze (4 sessions) — volatility is compressed. On-balance volume is trending down.
Key levels
The chart pattern's support is $4.22 and its resistance $5.39. The 52-week range is $1.33 to $5.43; price is 7.5% below the high and 277.4% above the low. The VWAP anchored at the 52-week high is $4.75, below price.
Performance
OABI returned -1.8% (1 week), +7.7% (1 month), +48.1% (3 months), +202.4% (6 months), +252.3% (1 year), +171.3% (year to date).
About OmniAb, Inc.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Services-Commercial Physical & Biological Research · Listed 2022 · 89 employees
Insider activity
SEC Form 4 transactions in OABI
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Love Steven Director · Common Stock · 2026-11-01 | Exercise | 13.33K | — | 2026-11-01 | 2026-11-02 |
Love Steven Director · Restricted Stock Units · 2026-11-01 | Exercise | 13.33K | — | 2026-11-01 | 2026-11-02 |
Crouse Steven C. Director · Restricted Stock Units · 2026-06-17 | Exercise | 20K | — | 2026-06-17 | 2026-06-18 |
Crouse Steven C. Director · Restricted Stock Units · 2026-06-17 | Grant | 20K | — | 2026-06-17 | 2026-06-18 |
Crouse Steven C. Director · Stock Option (right to buy) · 2026-06-17 | Grant | 40K | — | 2026-06-17 | 2026-06-18 |
Love Steven Director · Common Stock · 2026-06-17 | Exercise | 20K | — | 2026-06-17 | 2026-06-18 |
Bertozzi Carolyn R Director · Common Stock · 2026-06-17 | Exercise | 20K | — | 2026-06-17 | 2026-06-18 |
Bertozzi Carolyn R Director · Restricted Stock Units · 2026-06-17 | Exercise | 20K | — | 2026-06-17 | 2026-06-18 |
Bertozzi Carolyn R Director · Restricted Stock Units · 2026-06-17 | Grant | 20K | — | 2026-06-17 | 2026-06-18 |
Bertozzi Carolyn R Director · Stock Option (right to buy) · 2026-06-17 | Grant | 40K | — | 2026-06-17 | 2026-06-18 |
SEC filings
EDGAR filings in OABI · 4 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.